ALFA Finder| Management target | Net Profit FY27 |
|---|
| Margins | EBITDA margin at 30.9%; expected improvement Q-on-Q. |
|---|---|
| Demand visibility | Strong flu season in SA; cyclical orders in international markets. |
| Management confidence | High on oncology pipeline and international diversification. |
Growth
Revenue fell from INR 1,390.6 Cr YoY due to lower Lenalidomide sales. Brazil revenue surged 180% to INR 178 Cr.
Outlook
Management maintained FY27 PAT guidance of INR 750 Cr. Planning INR 2,000 Cr fundraise for potential M&A opportunities.
Risks
Seasonal demand cycles in South Africa; high R&D spend volatility; competitive pricing in the semaglutide market.
Last quarter's promises, checked
Delivered
- Guided FY26 PAT INR 1,400 Cr → delivered INR 1,418.5 Cr (= BEAT)
- Guided FY26 net cash INR 2,400 Cr → delivered INR 2,400 Cr (= BEAT)
- Guided Brazil sub revenue INR 730 Cr → delivered INR 730 Cr (= BEAT)
Partly delivered
- Guided R&D spend 7-9% → delivered elevated Q4 spend due to write-downs (= PARTIAL)
Missed
- Guided FY26 Revenue INR 4,784 Cr → delivered INR 4,375.9 Cr (= MISS)
Investor Presentation filed with BSE, NSE: NATCOPHARM. Summary written with AI assistance from the document.
Natco Pharma Ltd: key numbers
- Share price
- ₹808.95
- Market cap
- ₹15,869 Cr
- Revenue (annual)
- ₹4,078 Cr
- Net profit (annual)
- ₹1,418 Cr
- P/E (TTM)
- 13.9×Sector 43.8×
- Promoter holding
- 46.22%-3.20% QoQ
- FII holding
- 15.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Natco Pharma Ltd
All →Natco Pharma Share Pledge
Natco Pharma promoter V.C. Nannapaneni pledged 8,50,000 equity shares to Bajaj Financial Securities Limited. The pledge supports the promoter's subscription to the company's Rights Issue.
Natco Pharma Other Announcement
Natco Pharma filed its shareholding pattern with a reporting date of 23 October 2026. Promoter and promoter group hold about 46% of total equity.
Natco Pharma Capital Structure Change
Natco Pharma allotted 5,86,666 equity shares to promoter Venkaiah Chowdary Nannapaneni via its rights issue, valued at ~₹44 Crore. This lifts his stake to 14.60%.
- Value
- ₹44.00 Cr
Natco Pharma Employee Stock Options
Natco Pharma's insiders, including promoters and directors, were allotted equity shares. This allotment increases their total shareholding in the company.
- Value
- ₹144.2 Cr
Natco Pharma Board Meeting Date
Natco Pharma will hold a board meeting on 13 November 2026 to consider unaudited quarterly results and an interim dividend. Trading window closed until 15 November 2026.
Natco Pharma Capital Structure Change
Natco Pharma's ₹1,279.4 Crore rights issue closed on October 22, 2026. Shares were priced at ₹750 each on a ₹2 face value.
- Value
- ₹1,279 Cr